about
Validation of diagnostic codes for subtrochanteric, diaphyseal, and atypical femoral fractures using administrative claims data.Physician preference motivates the use of anti-tumor necrosis factor therapy independent of clinical disease activity.Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry.The association between serum vitamin D Level and disease activity in Thai rheumatoid arthritis patients.Serum procalcitonin as a diagnostic aid in patients with acute bacterial septic arthritis.Factors associated with osteonecrosis in Thai lupus patients: a case control study.The good EULAR response at the first year is strongly predictive of clinical remission in rheumatoid arthritis: results from the TARAC cohort.2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.Evidence-based recommendations for the diagnosis and management of rheumatoid arthritis for non-rheumatologists: Integrating systematic literature research and expert opinion of the Thai Rheumatism Association.Lupus Damage and Waist Circumference as the Independent Risk Factors for Cardiovascular Disease in SLE Patients from Phramongkutklao Hospital.Health-related quality of life and disease severity of SLE patients in Phramongkutklao Hospital.Effectiveness and Drug Survival of Anti-Tumor Necrosis Factor α Therapies in Patients With Spondyloarthritis: Analysis From the Thai Rheumatic Disease Prior Authorization Registry.Effect of patient education on medication adherence of patients with rheumatoid arthritis: a randomized controlled trialGroup B streptococcus is the most common pathogen for septic arthritis with unique clinical characteristics: data from 12 years retrospective cohort studyEfficacy and Safety of Hepatitis B Vaccination in Rheumatoid Arthritis Patients Receiving Disease-Modifying Antirheumatic Drugs and/or Biologics TherapyFactors associated with and cutoff points for Patient Acceptable Symptom State (PASS) in rheumatoid arthritisProlonged clinical remission and low disease activity statuses are associated with better quality of life in systemic lupus erythematosusDisease activity is associated with cognitive impairment in patients with rheumatoid arthritisPrevalence of and factors associated with depression and anxiety in patients with rheumatoid arthritis: A multicenter prospective cross-sectional studyHealth-related quality of life in patients with rheumatoid arthritisClinical spectrums and outcomes of necrotizing autoimmune myopathy versus other idiopathic inflammatory myopathies: a multicenter case-control studyEffect of Curcumin on Serum Urate in Asymptomatic Hyperuricemia: A Randomized Placebo-Controlled TrialReliability and validity of the Thai version of bath ankylosing spondylitis indices
P50
Q33958113-73FBE42A-9FEA-4C86-B671-5CC188EA8FB8Q34033597-0EBB7C1C-64E7-4922-A5CB-528071214A63Q38664981-71E9BC12-E545-4E58-886E-95CFC99B7326Q40149567-C5568677-9D3C-44C1-A309-46C4787C60C8Q41621139-D9580C7A-C2AD-400B-A995-0A3A4EF2670CQ43222206-59BFD2D9-5B35-4DE1-8C52-C2E8D494A797Q46081724-A662C306-F3A1-4EE9-9F2D-D1900C66F9F7Q48089791-2BB55EEA-31A4-49EE-902E-7473433E42CFQ49160612-50135528-2052-462B-9E2D-43D67EF0484EQ50889533-494ED054-1814-49A2-91F2-330474A68BD7Q51816893-923093C6-908B-401C-B25B-B97F7A76DF35Q52667028-204BF34D-85E4-4FF4-A499-A10A4CD68A0CQ60912117-9E6E8800-EA4C-426A-97D2-23170241411CQ90172828-38DD68F0-D4DD-40AE-B74A-CAE46033B4BDQ90611295-9A7B4701-CD54-45BB-B0FF-3240EB2C6728Q91858153-5346645E-68A7-481A-9336-2721A059CE0EQ91893546-F21D1337-47A9-43FF-B51C-4A1F6896ECC5Q92218718-BD365EF2-9129-4B4D-87E0-1671B26B9578Q92459177-4D65065E-BD1F-4396-A559-B3C8BBD898B7Q92716760-202AD026-870D-4F80-B544-9B99AE7CE716Q92850194-51A680AE-BCB4-426D-B2DB-EFFC8E187BFCQ95271619-CE4403DE-D648-4169-A884-E2071D173A4FQ95415680-B8421754-2E35-45D7-940A-7FED331969AD
P50
description
researcher ORCID ID = 0000-0001-8202-6746
@en
wetenschapper
@nl
name
Pongthorn Narongroeknawin
@ast
Pongthorn Narongroeknawin
@en
Pongthorn Narongroeknawin
@es
Pongthorn Narongroeknawin
@nl
type
label
Pongthorn Narongroeknawin
@ast
Pongthorn Narongroeknawin
@en
Pongthorn Narongroeknawin
@es
Pongthorn Narongroeknawin
@nl
prefLabel
Pongthorn Narongroeknawin
@ast
Pongthorn Narongroeknawin
@en
Pongthorn Narongroeknawin
@es
Pongthorn Narongroeknawin
@nl
P1153
35099091000
P31
P496
0000-0001-8202-6746